Recent months and years have seen significant advances in our understanding of glaucoma. Much has been learned, not only about damage mechanisms and pathogenesis, but also about diagnosis and management. Treatment options – both medical and surgical – continue to expand. This program will review this new knowledge with an emphasis on incorporating recent insights into day-to-day practice.
Glaucoma Now is a continuing medical education publication.
Distributed worldwide our goal is to educate and update general ophthalmologists, glaucoma specialists and ophthalmology residents.
International leaders in the field of glaucoma are invited to contribute to this journal, sharing their most recent insights.
Supported by an unrestricted educational grant, the publication is non-promotional and has a fully independent Editorial Board.
Supporting companies are: Allergan plc, Mundipharma Australia, Novartis Pharmaceuticals Australia Pty Ltd, and Pfizer Inc.
For each individual issue, Glaucoma Now is obtaining accreditation for Continuing Medical Education (CME) by the Physicians’ Chamber of Baden-Württemberg, Germany (Local Medical Responsible: Andreas Buchholz, MD, PhD, ROph). CME approval by the Physicians' Chamber of Baden-Württemberg, Germany has been granted for all issues since 2012, automatically implying acceptance of credits throughout the European Union and associated countries.
Glaucoma Now is also recognized by the Royal Australian and New Zealand College of Ophthalmologists as a valid Continuing Professional Development activity, and by the Brazilian Council of Ophthalmology (CBO).
Contributing specialists have an implied responsibility to use newly acquired information to enhance patient outcomes and professional development. The information presented in this activity is not meant to serve as a guideline for patient care. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Finally, and despite all our efforts, information or topics may be missing: please do let us know by sending an email to our editorial manager Dr. Patricia Buchholz at firstname.lastname@example.org
We hope you enjoy surfing on this new website.
The Editorial Board
Ivan Goldberg and Remo Susanna